Avalo Therapeutics (AVTX) director granted 20,100 stock options at $13.96 strike

Rhea-AI Filing Summary

Avalo Therapeutics director Rita Jain received a new stock option grant. The award covers 20,100 options to buy Avalo Therapeutics common stock at an exercise price of $13.96 per share, with all options vesting 100% on the first anniversary of the grant date, subject to her continued board service.

Following this compensation-related grant, Jain holds 20,100 stock options directly, and the options are scheduled to expire on June 2, 2036. The filing does not show any open‑market purchases or sales of Avalo Therapeutics shares, only this option award.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Jain Rita

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	20,100	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 20,100 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 20,100 options Exercise price: $13.96/share Options after transaction: 20,100 options +1 more

4 metrics

Option grant size 20,100 options Stock Option (Right to Buy) granted to director Rita Jain

Exercise price $13.96/share Conversion or exercise price of granted stock options

Options after transaction 20,100 options Total stock options held following this grant

Expiration date June 2, 2036 Option expiration for this grant

Key Terms

Stock Option (Right to Buy), exercise price, Grant, award, or other acquisition, vests 100% on the first anniversary

4 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

exercise price financial

"conversion_or_exercise_price: "13.9600""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

vests 100% on the first anniversary financial

"The stock option vests 100% on the first anniversary of the date of grant"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jain Rita

(Last) (First) (Middle)

C/O AVALO THERAPEUTICS, INC.

1500 LIBERTY RIDGE DRIVE, SUITE 321

(Street)

WAYNE PENNSYLVANIA 19087

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Avalo Therapeutics, Inc. [ AVTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$13.96	06/02/2026		A		20,100		(1)	06/02/2036	Common Stock	20,100	$0	20,100	D

Explanation of Responses:

1. The stock option vests 100% on the first anniversary of the date of grant, subject to the director's continued service on such vesting date.

	/s/ Christopher Sullivan, Attorney-in-Fact	06/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Avalo Therapeutics (AVTX) director Rita Jain report in this Form 4?

Rita Jain reported receiving 20,100 stock options as a compensation grant. These options give her the right to buy Avalo Therapeutics common stock at a fixed exercise price, with no open-market share purchases or sales disclosed in this filing.

How many Avalo Therapeutics (AVTX) options did Rita Jain receive and at what price?

Rita Jain received 20,100 stock options with an exercise price of $13.96 per share. This means she can buy up to 20,100 Avalo Therapeutics common shares at $13.96 if and when the options vest and are exercised.

When do Rita Jain’s Avalo Therapeutics (AVTX) stock options vest and expire?

The stock options vest 100% on the first anniversary of the grant date, if she continues serving as a director. The options are scheduled to expire on June 2, 2036, giving a long exercise window after vesting, subject to plan terms.

Does this Avalo Therapeutics (AVTX) Form 4 show insider buying or selling in the market?

The Form 4 shows a grant of 20,100 stock options as compensation, not an open-market trade. There are no reported open-market purchases or sales of Avalo Therapeutics common stock; the transaction is a derivative award with a $13.96 exercise price.

How many Avalo Therapeutics (AVTX) options does Rita Jain hold after this grant?

After this transaction, Rita Jain holds 20,100 stock options directly. This total matches the size of the reported grant, indicating the filing reflects her current option position from this award only, with no remaining derivative positions listed elsewhere.